What does Ossiform make?

Ossiform makes 3D-printed bone substitutes from β-tricalcium phosphate, a ceramic that resorbs as the patient's own bone grows in. They also produce the P3D Scaffold range for preclinical bone research. The clinical product has not yet received regulatory clearance.

Where is Ossiform based?

Ossiform ApS is registered and based in Odense, Denmark, at Oslogade 1, 5000 Odense C. The researcher's note associates the technology with the University of Leeds, though the company's own site does not describe a Leeds base.

Is Ossiform Bone approved for sale?

No. As stated on the Ossiform website, the Ossiform Bone has not been cleared by regulatory authorities and is not approved for sale. All testing to date has been preclinical, and the company cautions that in vitro and in vivo results may not predict clinical performance.

When was Ossiform founded?

The founders began investigating their TCP bone substitute approach in 2015, drawing on twelve prior years of bone tissue engineering research. The company is registered as Ossiform ApS.

What is the Ossiform Research Line?

The Ossiform Research Line is a range of 3D-printed bioceramic scaffolds — the P3D Scaffolds — designed for researchers rather than clinical use. They serve as animal-free substrates for bone tissue engineering, cancer research, disease modelling and drug screening, and have been featured in peer-reviewed publications.

Who are the key people at Ossiform?

Monica Wellejus is Chief Commercial Officer and has represented the company at industry events including a 3DHEALS bioprinting conference in April 2026. Gijs Klarenbeek, MD, joined in April 2026 as Clinical and Medical Affairs Advisor, also carrying the title of Chief Medical Officer in subsequent announcements.

MedTech / 3D Printing · Small, under 15 employees

Ossiform

3D-printed tricalcium phosphate bone substitutes

ossiform.com ↗Founded 2015

Ossiform is a Danish MedTech company developing 3D-printed bone substitutes made from β-tricalcium phosphate (TCP). Their implants are designed to remodel into vascularised bone over time, removing the need for permanent foreign-body implants or donor allografts. They also supply a research product line — the P3D Scaffolds — for preclinical bone tissue engineering and cell culture work.

What they do

Ossiform develops structural bone substitutes that are 3D-printed from β-tricalcium phosphate, a bioactive ceramic that the body can resorb and replace with new vascularised bone. The core product, Ossiform Bone, is anatomically contoured to match a patient's defect geometry and is engineered with indication-specific biomechanical properties to support load-bearing during healing. The stated aim is to give surgeons a consistent, resorbable alternative to permanent metal implants and to the quality variability that comes with donor allografts.

The company describes the underlying technology as originating from a novel bio-ink formulation that can be 3D-printed into structurally tailored, resorbable forms. That work began in 2015, when the founders started investigating replacements for destroyed or surgically removed bone. The research draws on twelve years of prior work in bone tissue engineering, during which the founders concluded that existing solutions were addressing the wrong clinical problems.

It is worth being clear about regulatory status: as of the published site text, Ossiform Bone has not been cleared by regulatory authorities and is not approved for sale. Testing to date has been preclinical only, and the company notes that in vitro and in vivo results may not predict clinical performance.

Alongside the clinical-track product, Ossiform runs a separate research line. The P3D Scaffolds are bioceramic, bone-mimicking cell culture scaffolds aimed at researchers who want a clinically relevant, animal-free substrate for studies in bone tissue engineering, disease modelling, cancer research and drug screening. These are available now and are supported by published peer-reviewed work — a 2026 ACS Omega study featured the P3D Scaffolds, and the company has presented findings at events including a 3DHEALS bioprinting conference.

What sets them apart

Most bone reconstruction today relies on either permanent implants — titanium plates, cages, prostheses — or on allografts sourced from donor tissue. Both carry well-documented drawbacks. Permanent implants remain in the body indefinitely, can cause stress shielding and may require revision surgery. Allografts introduce variability in quality and carry supply constraints. Ossiform's pitch is that a resorbable, patient-specific ceramic implant sidesteps both problems: it provides structural support during healing and then disappears as the patient's own bone grows in.

The TCP material is osteoconductive and biocompatible, meaning it supports bone cell attachment and ingrowth without triggering an immune response. The 3D-printing process allows the porosity, geometry and mechanical properties to be tuned per indication, which is harder to achieve with machined or cast ceramics.

In April 2026, Ossiform appointed Gijs Klarenbeek, MD, as Clinical and Medical Affairs Advisor — a signal that the company is building out the clinical and regulatory infrastructure needed to move toward market approval. The same month, a distribution partnership with Imbros Pty Ltd was announced, covering an unspecified territory. Monica Wellejus holds the role of Chief Commercial Officer; Klarenbeek carries the title of Chief Medical Officer in later news items.

Ossiform is registered as Ossiform ApS and is based at Oslogade 1, 5000 Odense C, Denmark. The researcher's note flags a University of Leeds spinout connection, though the company's own published material does not explicitly describe that origin. The registered address and contact details point firmly to Odense as the operational base.

What they offer

Ossiform Bone — 3D-printed β-tricalcium phosphate structural bone substitute, anatomically contoured per patient; preclinical stage only, not yet regulatory-cleared.
P3D Scaffolds (Ossiform Research Line) — bioceramic bone-mimicking scaffolds for cell culture, tissue engineering, disease modelling and drug screening; available to researchers now.
Cell Culture Plates — listed as a separate product under the Research Line, supporting in vitro bone and cancer research workflows.

FAQs

What does Ossiform make?: Ossiform makes 3D-printed bone substitutes from β-tricalcium phosphate, a ceramic that resorbs as the patient's own bone grows in. They also produce the P3D Scaffold range for preclinical bone research. The clinical product has not yet received regulatory clearance.
Where is Ossiform based?: Ossiform ApS is registered and based in Odense, Denmark, at Oslogade 1, 5000 Odense C. The researcher's note associates the technology with the University of Leeds, though the company's own site does not describe a Leeds base.
Is Ossiform Bone approved for sale?: No. As stated on the Ossiform website, the Ossiform Bone has not been cleared by regulatory authorities and is not approved for sale. All testing to date has been preclinical, and the company cautions that in vitro and in vivo results may not predict clinical performance.
When was Ossiform founded?: The founders began investigating their TCP bone substitute approach in 2015, drawing on twelve prior years of bone tissue engineering research. The company is registered as Ossiform ApS.
What is the Ossiform Research Line?: The Ossiform Research Line is a range of 3D-printed bioceramic scaffolds — the P3D Scaffolds — designed for researchers rather than clinical use. They serve as animal-free substrates for bone tissue engineering, cancer research, disease modelling and drug screening, and have been featured in peer-reviewed publications.
Who are the key people at Ossiform?: Monica Wellejus is Chief Commercial Officer and has represented the company at industry events including a 3DHEALS bioprinting conference in April 2026. Gijs Klarenbeek, MD, joined in April 2026 as Clinical and Medical Affairs Advisor, also carrying the title of Chief Medical Officer in subsequent announcements.